Paula Munderi

Summary

Affiliation: MRC/UVRI Uganda Research Unit on AIDS
Country: Uganda

Publications

  1. doi request reprint What are the essential components of HIV treatment and care services in low and middle-income countries: an overview by settings and levels of the health system?
    Paula Munderi
    MRC UVRI Research Unit on AIDS in Uganda, Uganda Virus Research Institute, Entebbe, Uganda
    AIDS 26:S97-S103. 2012
  2. doi request reprint When to start antiretroviral therapy in adults in low- and middle-income countries: science and practice
    Paula Munderi
    MCR UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda
    Curr Opin HIV AIDS 5:6-11. 2010
  3. doi request reprint Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring
    Fred Lyagoba
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    J Acquir Immune Defic Syndr 55:277-83. 2010
  4. doi request reprint Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir
    Nicaise Ndembi
    Uganda Research Unit on AIDS, Medical Research Council MRC Uganda Virus Research Institute, Entebbe, Kampala, Uganda
    J Infect Dis 201:106-13. 2010
  5. doi request reprint Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe
    Sylvia K Muyingo
    MRC Uganda Research Unit on AIDS, Entebbe, Uganda
    J Acquir Immune Defic Syndr 48:468-75. 2008
  6. doi request reprint The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis
    Barbara Nyanzi-Wakholi
    MRC UVRI Uganda Research Unit on AIDS, Department of Social Sciences, Entebbe, Uganda
    AIDS Care 21:903-8. 2009
  7. doi request reprint Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults
    George Miiro
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    Trop Med Int Health 14:556-63. 2009
  8. doi request reprint Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART
    Paula Munderi
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    Trop Med Int Health 16:200-4. 2011
  9. doi request reprint The charms and challenges of antiretroviral therapy in Uganda: the DART experience
    Barbara Nyanzi-Wakholi
    MRC UVRI Uganda AIDS Research Unit, Entebbe, Uganda
    AIDS Care 24:137-42. 2012
  10. doi request reprint Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy
    Patricia Nahirya-Ntege
    MRC UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda
    Pediatr Infect Dis J 30:535-7. 2011

Collaborators

Detail Information

Publications12

  1. doi request reprint What are the essential components of HIV treatment and care services in low and middle-income countries: an overview by settings and levels of the health system?
    Paula Munderi
    MRC UVRI Research Unit on AIDS in Uganda, Uganda Virus Research Institute, Entebbe, Uganda
    AIDS 26:S97-S103. 2012
    ..To review and summarize the essential components of HIV treatment and care services in low and middle-income countries (LMICs)...
  2. doi request reprint When to start antiretroviral therapy in adults in low- and middle-income countries: science and practice
    Paula Munderi
    MCR UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda
    Curr Opin HIV AIDS 5:6-11. 2010
    ....
  3. doi request reprint Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring
    Fred Lyagoba
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    J Acquir Immune Defic Syndr 55:277-83. 2010
    ..To describe the resistance mutations selected by a first-line regimen of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring...
  4. doi request reprint Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir
    Nicaise Ndembi
    Uganda Research Unit on AIDS, Medical Research Council MRC Uganda Virus Research Institute, Entebbe, Kampala, Uganda
    J Infect Dis 201:106-13. 2010
    ..We investigated virological response and the emergence of resistance in the Nevirapine or Abacavir (NORA) substudy of the Development of Antiretroviral Treatment in Africa (DART) trial...
  5. doi request reprint Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe
    Sylvia K Muyingo
    MRC Uganda Research Unit on AIDS, Entebbe, Uganda
    J Acquir Immune Defic Syndr 48:468-75. 2008
    ..Good adherence is essential for successful antiretroviral therapy (ART) provision, but simple measures have rarely been validated in Africa...
  6. doi request reprint The role of HIV testing, counselling, and treatment in coping with HIV/AIDS in Uganda: a qualitative analysis
    Barbara Nyanzi-Wakholi
    MRC UVRI Uganda Research Unit on AIDS, Department of Social Sciences, Entebbe, Uganda
    AIDS Care 21:903-8. 2009
    ..Based on this study's findings, ensuring the provision of quality assured and gender conscious VCT and ART delivery services will enhance positive living and enforce compliance to ART programmes...
  7. doi request reprint Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults
    George Miiro
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    Trop Med Int Health 14:556-63. 2009
    ..To evaluate the effect of highly active anti-retroviral therapy (HAART) and cotrimoxazole prophylaxis on morbidity after HAART eligibility...
  8. doi request reprint Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART
    Paula Munderi
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    Trop Med Int Health 16:200-4. 2011
    ..To determine the frequencies of HLA-B alleles in Ugandan patients in the NORA substudy of the DART trial and to compare HLA-B allele frequencies in those with and without clinically diagnosed hypersensitivity reaction (HSR)...
  9. doi request reprint The charms and challenges of antiretroviral therapy in Uganda: the DART experience
    Barbara Nyanzi-Wakholi
    MRC UVRI Uganda AIDS Research Unit, Entebbe, Uganda
    AIDS Care 24:137-42. 2012
    ..ART was perceived as improving the overall quality of life of recipients; however, it is crucial for ART programmes to be gender and socio-economic cognizant in order to enhance adherence to a lifelong therapy...
  10. doi request reprint Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy
    Patricia Nahirya-Ntege
    MRC UVRI Uganda Research Unit on AIDS, Uganda Virus Research Institute, Entebbe, Uganda
    Pediatr Infect Dis J 30:535-7. 2011
    ..3%; 95% CI, 0.01-0.9). Patients were managed successfully through the provision of clear guidelines and education of clinical staff, children, and their caregivers...
  11. pmc CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy
    Jennifer Serwanga
    MRC UVRI Uganda Research Unit on AIDS, 51 59 Nakiwogo Road, Entebbe, Uganda
    AIDS Res Treat 2011:875028. 2011
    ..These data add to others that found no evidence to support STI as a strategy to improve HIV-specific immunity during ART...
  12. ncbi request reprint Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy
    Ben Kikaire
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    AIDS 21:733-7. 2007
    ..To measure nevirapine elimination in African adults undertaking a structured treatment interruption (STI) in the DART trial...